Delayed
BME
11:35:10 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
84.3
EUR
|
+1.93%
|
|
+6.10%
|
+40.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,351
|
2,099
|
4,138
|
1,925
|
3,213
|
4,368
|
-
|
-
|
Enterprise Value (EV)
1 |
1,369
|
2,121
|
4,112
|
1,872
|
3,251
|
4,330
|
4,221
|
4,062
|
P/E ratio
|
34.4
x
|
34.5
x
|
26.7
x
|
9.67
x
|
18.8
x
|
25.5
x
|
21.9
x
|
16.6
x
|
Yield
|
0.72%
|
1.01%
|
1.29%
|
3.59%
|
1.83%
|
1.33%
|
1.53%
|
1.92%
|
Capitalization / Revenue
|
3.54
x
|
5
x
|
6.38
x
|
2.35
x
|
3.87
x
|
5.3
x
|
4.85
x
|
4.18
x
|
EV / Revenue
|
3.59
x
|
5.05
x
|
6.34
x
|
2.29
x
|
3.92
x
|
5.25
x
|
4.69
x
|
3.88
x
|
EV / EBITDA
|
22.5
x
|
22.5
x
|
20.3
x
|
6.72
x
|
13.3
x
|
17.8
x
|
14.8
x
|
11
x
|
EV / FCF
|
-39.2
x
|
281
x
|
37.9
x
|
10.1
x
|
54.3
x
|
27.8
x
|
25.9
x
|
18.9
x
|
FCF Yield
|
-2.55%
|
0.36%
|
2.64%
|
9.95%
|
1.84%
|
3.6%
|
3.86%
|
5.3%
|
Price to Book
|
4.19
x
|
5.62
x
|
8.59
x
|
3.71
x
|
-
|
6.92
x
|
5.61
x
|
4.46
x
|
Nbr of stocks (in thousands)
|
55,382
|
55,393
|
56,069
|
53,375
|
53,370
|
51,820
|
-
|
-
|
Reference price
2 |
24.40
|
37.90
|
73.80
|
36.06
|
60.20
|
84.30
|
84.30
|
84.30
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/23/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
381.3
|
420
|
648.7
|
817.7
|
829.5
|
824.4
|
900
|
1,046
|
EBITDA
1 |
60.86
|
94.33
|
202.9
|
278.7
|
244.5
|
242.9
|
285.5
|
368.6
|
EBIT
1 |
42.65
|
74.74
|
181.5
|
255.8
|
220.1
|
217.1
|
258
|
339.3
|
Operating Margin
|
11.18%
|
17.8%
|
27.98%
|
31.29%
|
26.53%
|
26.34%
|
28.67%
|
32.43%
|
Earnings before Tax (EBT)
1 |
41.88
|
72.58
|
182.6
|
258
|
220.4
|
213.2
|
251
|
326.4
|
Net income
1 |
39.27
|
61.06
|
153.1
|
199.7
|
170.3
|
170.7
|
203.6
|
269.7
|
Net margin
|
10.3%
|
14.54%
|
23.6%
|
24.42%
|
20.53%
|
20.71%
|
22.62%
|
25.77%
|
EPS
2 |
0.7100
|
1.100
|
2.760
|
3.730
|
3.200
|
3.311
|
3.850
|
5.093
|
Free Cash Flow
1 |
-34.94
|
7.539
|
108.5
|
186.2
|
59.9
|
155.7
|
163
|
215.1
|
FCF margin
|
-9.16%
|
1.8%
|
16.73%
|
22.77%
|
7.22%
|
18.89%
|
18.11%
|
20.56%
|
FCF Conversion (EBITDA)
|
-
|
7.99%
|
53.49%
|
66.81%
|
24.5%
|
64.11%
|
57.08%
|
58.37%
|
FCF Conversion (Net income)
|
-
|
12.35%
|
70.88%
|
93.26%
|
35.17%
|
91.2%
|
80.03%
|
79.78%
|
Dividend per Share
2 |
0.1751
|
0.3812
|
0.9556
|
1.294
|
1.104
|
1.121
|
1.289
|
1.622
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/23/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
191.1
|
290
|
173.5
|
185.2
|
205.6
|
174.8
|
380.4
|
195.1
|
242.2
|
201.6
|
179.2
|
380.8
|
214
|
234.8
|
153.3
|
EBITDA
1 |
42.41
|
74
|
65.5
|
63.35
|
74.3
|
41.5
|
115.8
|
58.1
|
104.8
|
66.5
|
30.6
|
97.1
|
74.1
|
73.3
|
26.25
|
EBIT
1 |
32.89
|
63.24
|
60.05
|
58.2
|
68.71
|
35.65
|
104.4
|
52.47
|
99.02
|
60.7
|
24.51
|
85.21
|
68.2
|
66.7
|
20.57
|
Operating Margin
|
17.21%
|
21.8%
|
34.62%
|
31.43%
|
33.42%
|
20.39%
|
27.43%
|
26.89%
|
40.88%
|
30.11%
|
13.67%
|
22.37%
|
31.86%
|
28.41%
|
13.42%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
60.44
|
58.28
|
68.93
|
-
|
-
|
-
|
-
|
61.2
|
-
|
-
|
-
|
-
|
19.8
|
Net income
1 |
29.59
|
51.02
|
47.92
|
54.14
|
53.05
|
27.57
|
80.62
|
40.88
|
78.16
|
47.5
|
19.1
|
66.6
|
52.22
|
51.48
|
11.93
|
Net margin
|
15.48%
|
17.59%
|
27.62%
|
29.24%
|
25.8%
|
15.77%
|
21.19%
|
20.95%
|
32.27%
|
23.56%
|
10.66%
|
17.49%
|
24.4%
|
21.93%
|
7.79%
|
EPS
|
-
|
-
|
-
|
0.9800
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/27/20
|
7/28/21
|
11/3/21
|
2/23/22
|
5/11/22
|
7/27/22
|
7/27/22
|
11/4/22
|
2/21/23
|
5/10/23
|
7/26/23
|
7/26/23
|
11/8/23
|
2/27/24
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
17.4
|
21.3
|
-
|
-
|
38.6
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
25.9
|
52.8
|
-
|
38.2
|
147
|
306
|
Leverage (Debt/EBITDA)
|
0.2855
x
|
0.2256
x
|
-
|
-
|
0.1579
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
-34.9
|
7.54
|
109
|
186
|
59.9
|
156
|
163
|
215
|
ROE (net income / shareholders' equity)
|
12.9%
|
17.5%
|
36.2%
|
40.3%
|
32.2%
|
29%
|
28.3%
|
30.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
23.4%
|
24.8%
|
21.3%
|
19.6%
|
21%
|
24.6%
|
Assets
1 |
-
|
-
|
653.6
|
805.7
|
799.7
|
871.1
|
969.7
|
1,096
|
Book Value Per Share
2 |
5.820
|
6.750
|
8.590
|
9.730
|
-
|
12.20
|
15.00
|
18.90
|
Cash Flow per Share
|
-0.1600
|
0.8500
|
2.700
|
4.440
|
-
|
-
|
-
|
-
|
Capex
1 |
25.9
|
39.3
|
40.9
|
51.4
|
55.2
|
48.9
|
43.7
|
36.8
|
Capex / Sales
|
6.79%
|
9.37%
|
6.31%
|
6.28%
|
6.65%
|
5.93%
|
4.86%
|
3.52%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/23/22
|
2/21/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
84.3
EUR Average target price
85.12
EUR Spread / Average Target +0.98% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.03% | 4.67B | | +34.00% | 704B | | +25.80% | 577B | | -7.75% | 348B | | +18.53% | 327B | | +4.95% | 288B | | +15.21% | 234B | | +4.93% | 198B | | -9.78% | 194B | | -4.89% | 147B |
Other Pharmaceuticals
|